Formulated and/or co-formulated liposome compositions containing TFGB antagonist prodrugs useful in the treatment of cancer and methods thereof
AssigneeNammi Therapeutics, Inc.
InventorsDavid Stover, Dhruba Bharali, Bruce A. Hay, Tahmineh Safaie
Life of this patent
Estimating the term…
Abstract
Formulated and/or co-formulated liposomes (LNP) and solid-lipid nanoparticles (SLNP) comprising TB Prodrugs and methods of making the LNPs and SLNPs are disclosed herein. The TB prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit ALK5. The TB Prodrugs can be formulated and/or co-formulated into a liposome or solid-lipid nanoparticle to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.
Claims20
1) A TB prodrug composition comprising,
- (i) a drug moiety;
- (ii) a lipid moiety;
- and
- (iii) a linkage unit (“LU”),
- whereby the drug moiety comprises a TGFβ antagonist and whereby the LU conjugates the drug moiety with the lipid moiety.
6) A nanocarrier comprising, a TB prodrug whereby the nanocarrier releases an active ALK5 inhibitor after cleavage of a LU.
20) A method of treating a subject suffering or diagnosed with cancer comprising,
- (i) administering to a subject in need of such treatment an effective amount of a nanocarrier, wherein the nanocarrier comprises a TB-Prodrug;
- and
- (ii) a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.